Scalp psoriasis people treated with anti-IL17 agents attained a faster decrease of the lesions. Regarding maintenance of the clinical improvement through the follow-up, the anti-IL23 monoclonal antibodies were slightly superior.

A study was carried out to retrospectively compare the effectiveness of anti-interleukin (IL)-23 drugs and anti-IL17 or anti-IL17 receptor A biologics in real-life people suffering from scalp psoriasis.

This single-center retrospective comparative study recruited 127 people having scalp psoriasis and  baseline scalp Physician Global Assessment ≥3. Overall,  65 people were treated with anti-IL23 agents (risankizumab, tildrakizumab, guselkumab) while 62 people were treated with anti-IL17 agents (brodalumab, ixekizumab, secukinumab). For assessing the percentage of response, statistical analysis through the χ2 test was carried out.

At Week 4, 16, 24, 48, 96, and 144, the responders' percentage of patients under anti-IL23 and anti-IL17 are shown in Table 1:

In patients with a clinical diagnosis of refractory scalp psoriasis, both anti-IL17 and anti-IL23 biologic drugs appeared to be effective.